X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (55) 55
humans (51) 51
cardiac & cardiovascular systems (46) 46
female (33) 33
male (33) 33
cardiovascular (28) 28
abridged index medicus (25) 25
middle aged (25) 25
aged (21) 21
heart failure (20) 20
cardiomyopathy (19) 19
internal medicine (19) 19
care and treatment (15) 15
chemotherapy (15) 15
amyloidosis (14) 14
heart diseases (14) 14
cancer (12) 12
mortality (12) 12
heart (11) 11
adult (10) 10
retrospective studies (10) 10
analysis (9) 9
antineoplastic agents - adverse effects (9) 9
congestive-heart-failure (9) 9
drug therapy (9) 9
echocardiography (9) 9
health aspects (9) 9
insulin resistance (9) 9
medicine, general & internal (9) 9
cardiotoxicity (8) 8
diagnosis (8) 8
patients (8) 8
prognosis (8) 8
transthyretin (8) 8
cardiology (7) 7
cardiology and cardiovascular medicine (7) 7
heart-failure (7) 7
medical colleges (7) 7
neoplasms - drug therapy (7) 7
transplantation (7) 7
ventricular dysfunction, left - chemically induced (7) 7
breast cancer (6) 6
cardiac amyloidosis (6) 6
disease (6) 6
follow-up studies (6) 6
glucose (6) 6
management (6) 6
peripheral vascular disease (6) 6
treatment outcome (6) 6
aged, 80 and over (5) 5
animals (5) 5
antineoplastic agents - therapeutic use (5) 5
cardiac patients (5) 5
diabetes (5) 5
heart failure - drug therapy (5) 5
hematology (5) 5
hypertension (5) 5
insulin (5) 5
risk (5) 5
risk factors (5) 5
rodents (5) 5
stem-cell transplantation (5) 5
surgery (5) 5
trastuzumab (5) 5
al amyloidosis (4) 4
amyloidosis - complications (4) 4
amyloidosis - drug therapy (4) 4
anthracyclines - adverse effects (4) 4
article (4) 4
breast-cancer (4) 4
cardiovascular disease (4) 4
cardiovascular diseases (4) 4
clinical trials (4) 4
complications and side effects (4) 4
dextrose (4) 4
education (4) 4
heart attacks (4) 4
heart diseases - chemically induced (4) 4
heart failure - chemically induced (4) 4
heart transplantation (4) 4
high-dose chemotherapy (4) 4
left-ventricular dysfunction (4) 4
mutation (4) 4
natriuretic peptide (4) 4
oncology (4) 4
patient outcomes (4) 4
phenotype (4) 4
polyneuropathy (4) 4
prevalence (4) 4
prevention (4) 4
stem cells (4) 4
studies (4) 4
survival (4) 4
survival rate - trends (4) 4
systemic amyloidosis (4) 4
therapy (4) 4
usage (4) 4
adjuvant chemotherapy (3) 3
adrenergic beta-antagonists - therapeutic use (3) 3
aging (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 04/2016, Volume 133, Issue 15, pp. e598 - e598
Journal Article
Journal of Cardiac Failure, ISSN 1071-9164, 03/2019, Volume 25, Issue 3, pp. 154 - 155
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2008, Volume 51, Issue 2, pp. 93 - 102
Journal Article
Journal of Cardiac Failure, ISSN 1071-9164, 2014, Volume 20, Issue 6, pp. 457 - 457
Journal Article
Nature Medicine, ISSN 1078-8956, 05/2016, Volume 22, Issue 5, pp. 547 - 556
Doxorubicin is an anthracycline chemotherapy agent effective in treating a wide range of malignancies, but it causes a dose-related cardiotoxicity that can... 
MEDICINE, RESEARCH & EXPERIMENTAL | OXIDATIVE STRESS | RISK-FACTORS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DEXRAZOXANE | INDUCED CARDIOMYOPATHY | MATURATION | MUSCLE GENE-EXPRESSION | CELL BIOLOGY | CHILDHOOD-CANCER | INHIBITION | ANTHRACYCLINE-INDUCED CARDIOTOXICITY | CONGESTIVE-HEART-FAILURE | Mitochondria, Heart - metabolism | Reactive Oxygen Species - metabolism | Antibiotics, Antineoplastic - pharmacology | Apoptosis - drug effects | Calcium - metabolism | Humans | Middle Aged | Transcriptome | Antibiotics, Antineoplastic - adverse effects | Mitochondria, Heart - drug effects | Membrane Potential, Mitochondrial - drug effects | Flow Cytometry | Adult | Female | Real-Time Polymerase Chain Reaction | Cardiotoxicity - genetics | DNA Damage - drug effects | Cell Survival - drug effects | Disease Susceptibility | Heart Failure - genetics | Breast Neoplasms - drug therapy | Myocytes, Cardiac - drug effects | Fluorescent Antibody Technique | Myocytes, Cardiac - metabolism | Aged | Polymorphism, Single Nucleotide | Oxidative Stress - drug effects | Induced Pluripotent Stem Cells | Doxorubicin - adverse effects | Doxorubicin - pharmacology | Heart Failure - chemically induced | Complications and side effects | Patient outcomes | Stem cells | Development and progression | Breast cancer | Transplantation | Cardiovascular diseases | Drug therapy | Doxorubicin | Methods | Heart failure | Chemotherapy | Toxicity | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9756, pp. 1903 - 1909
Journal Article
Blood, ISSN 0006-4971, 08/2017, Volume 130, Issue 7, pp. 900 - 902
The majority of patients with immunoglobulin light chain amyloidosis (AL) fail to achieve a complete response (CR) to standard light chain suppressive... 
STAGING SYSTEM | CHAIN | BORTEZOMIB | HEMATOLOGY | CYCLOPHOSPHAMIDE | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Female | Male | Aged | Amyloidosis - drug therapy | Amyloidosis - blood | Immunoglobulin Light Chains - metabolism | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 11/2010, Volume 56, Issue 20, pp. 1644 - 1650
Objectives: The purpose of this study was to examine treatment practices for cancer therapy-associated decreased left ventricular ejection fraction (LVEF)... 
Heart failure | Left ventricular dysfunction | Anthracyclines | Chemotherapy | Cancer | ADJUVANT CHEMOTHERAPY | heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | TRASTUZUMAB | ADULTS | left ventricular dysfunction | chemotherapy | HER2-POSITIVE BREAST-CANCER | TRIAL COMPARING DOXORUBICIN | LYMPHOMA | cancer | anthracyclines | CONGESTIVE-HEART-FAILURE | HER2 | PLUS | Anthracyclines - adverse effects | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Heart Ventricles - diagnostic imaging | Ventricular Dysfunction, Left - chemically induced | Dose-Response Relationship, Drug | Young Adult | Antibodies, Monoclonal, Humanized | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Antineoplastic Agents - adverse effects | Ultrasonography | Adult | Female | Retrospective Studies | Adrenergic beta-Antagonists - therapeutic use | Risk Factors | Stroke Volume - drug effects | Ventricular Dysfunction, Left - physiopathology | Neoplasms - drug therapy | Ventricular Dysfunction, Left - drug therapy | Heart Ventricles - physiopathology | Aged | Anthracyclines - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Trastuzumab | Breast cancer | Heart attacks | Drug therapy | Cancer therapies | Beta blockers | Leukemia | Index Medicus | Abridged Index Medicus | Angiotensin receptors
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 6/2013, Volume 110, Issue 24, pp. 9992 - 9997
The misassembly of soluble proteins into toxic aggregates, including amyloid fibrils, underlies a large number of human degenerative diseases. Cardiac... 
Aggregation | Exchange rates | Molecules | Familial amyloidosis | Ligands | Cardiomyopathies | Amyloids | Kinetics | Monomers | Binding sites | Drug design | Crystal structure | POLYNEUROPATHY | drug design | MULTIDISCIPLINARY SCIENCES | CARDIAC AMYLOIDOSIS | VARIANT | TRANSPLANTATION | HEART | DISSOCIATION | TAFAMIDIS | DISEASE | crystal structure | AFRICAN-AMERICANS | PROTEINS | Amyloidosis - prevention & control | Benzoxazoles - pharmacology | Prealbumin - genetics | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Rats, Wistar | Area Under Curve | Benzoates - chemistry | Humans | Benzoxazoles - metabolism | Cardiomyopathies - prevention & control | Crystallography, X-Ray | Dose-Response Relationship, Drug | Cardiomyopathies - genetics | Pyrazoles - chemistry | Amyloid - metabolism | MCF-7 Cells | Amyloidosis - genetics | Molecular Structure | Prealbumin - chemistry | Pyrazoles - pharmacokinetics | Protein Structure, Tertiary | Amyloid - antagonists & inhibitors | Amyloid - genetics | Cell Line | Cell Survival - drug effects | Models, Molecular | Rats | Mice, Inbred ICR | Animals | Prealbumin - metabolism | Cardiomyopathies - metabolism | Protein Stability - drug effects | Cell Line, Tumor | Protein Binding | Mice | HeLa Cells | Mutation | Amyloidosis - metabolism | Benzoates - pharmacokinetics | Benzoxazoles - pharmacokinetics | Proteins | Heart | African Americans | Cytotoxicity | Cells | Index Medicus | Biological Sciences
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2008, Volume 52, Issue 3, p. 239
  Whether treating whole-body insulin resistance will positively affect HF patients remains unclear, though preliminary evidence (6-8) favors using... 
Hyperglycemia | Cardiomyopathy | Rodents | Insulin resistance | Metabolism | Insulin
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2008, Volume 52, Issue 3, p. 239
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2008, Volume 52, Issue 3, pp. 239 - 240
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2008, Volume 52, Issue 3, pp. 239 - 240
Journal Article